An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ

Subjects

Abstract

Obesity-linked insulin resistance is a major precursor to the development of type 2 diabetes. Previous work has shown that phosphorylation of PPARγ (peroxisome proliferator-activated receptor γ) at serine 273 by cyclin-dependent kinase 5 (Cdk5) stimulates diabetogenic gene expression in adipose tissues1. Inhibition of this modification is a key therapeutic mechanism for anti-diabetic drugs that bind PPARγ, such as the thiazolidinediones and PPARγ partial agonists or non-agonists2. For a better understanding of the importance of this obesity-linked PPARγ phosphorylation, we created mice that ablated Cdk5 specifically in adipose tissues. These mice have both a paradoxical increase in PPARγ phosphorylation at serine 273 and worsened insulin resistance. Unbiased proteomic studies show that extracellular signal-regulated kinase (ERK) kinases are activated in these knockout animals. Here we show that ERK directly phosphorylates serine 273 of PPARγ in a robust manner and that Cdk5 suppresses ERKs through direct action on a novel site in MAP kinase/ERK kinase (MEK). Importantly, pharmacological inhibition of MEK and ERK markedly improves insulin resistance in both obese wild-type and ob/ob mice, and also completely reverses the deleterious effects of the Cdk5 ablation. These data show that an ERK/Cdk5 axis controls PPARγ function and suggest that MEK/ERK inhibitors may hold promise for the treatment of type 2 diabetes.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Insulin resistance after Cdk5 deletion in adipocytes.
Figure 2: Identification and characterization of ERK as a S273 PPARγ kinase.
Figure 3: Regulation of MEK2 by Cdk5.
Figure 4: Metabolic consequences of MEK inhibition in vivo in mice fed with a high-fat diet.
Figure 5: Metabolic consequences of MEK inhibition in ob/ob mice.

References

  1. 1

    Choi, J. H. et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5. Nature 466, 451–456 (2010)

    ADS  CAS  Article  Google Scholar 

  2. 2

    Choi, J. H. et al. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 477, 477–481 (2011)

    ADS  CAS  Article  Google Scholar 

  3. 3

    Yu, J. G. et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51, 2968–2974 (2002)

    CAS  Article  Google Scholar 

  4. 4

    Tontonoz, P., Hu, E. & Spiegelman, B. M. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79, 1147–1156 (1994)

    CAS  Article  Google Scholar 

  5. 5

    Chawla, A., Schwarz, E. J., Dimaculangan, D. D. & Lazar, M. A. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 135, 798–800 (1994)

    CAS  Article  Google Scholar 

  6. 6

    Saltiel, A. R. & Kahn, C. R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414, 799–806 (2001)

    ADS  CAS  Article  Google Scholar 

  7. 7

    Krüger, M. et al. Dissection of the insulin signaling pathway via quantitative phosphoproteomics. Proc. Natl Acad. Sci. USA 105, 2451–2456 (2008)

    ADS  Article  Google Scholar 

  8. 8

    De Fea, K. & Roth, R. A. Modulation of insulin receptor substrate-1 tyrosine phosphorylation and function by mitogen-activated protein kinase. J. Biol. Chem. 272, 31400–31406 (1997)

    CAS  Article  Google Scholar 

  9. 9

    Zheng, Y. et al. Improved insulin sensitivity by calorie restriction is associated with reduction of ERK and p70S6K activities in the liver of obese Zucker rats. J. Endocrinol. 203, 337–347 (2009)

    CAS  Article  Google Scholar 

  10. 10

    Lazar, D. F. et al. Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin. J. Biol. Chem. 270, 20801–20807 (1995)

    CAS  Article  Google Scholar 

  11. 11

    Jiang, Z. Y. et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J. Clin. Invest. 104, 447–457 (1999)

    CAS  Article  Google Scholar 

  12. 12

    Jager, J. et al. Deficiency in the extracellular signal-regulated kinase 1 (ERK1) protects leptin-deficient mice from insulin resistance without affecting obesity. Diabetologia 54, 180–189 (2011)

    CAS  Article  Google Scholar 

  13. 13

    Hawasli, A. H. et al. Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation. Nature Neurosci. 10, 880–886 (2007)

    CAS  Article  Google Scholar 

  14. 14

    Eguchi, J. et al. Transcriptional control of adipose lipid handling by IRF4. Cell Metab. 13, 249–259 (2011)

    CAS  Article  Google Scholar 

  15. 15

    Ohshima, T. et al. Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc. Natl Acad. Sci. USA 93, 11173–11178 (1996)

    ADS  CAS  Article  Google Scholar 

  16. 16

    Hawasli, A. H. et al. Regulation of hippocampal and behavioral excitability by cyclin-dependent kinase 5. PLoS ONE 4, e5808 (2009)

    ADS  Article  Google Scholar 

  17. 17

    Meijer, L. et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243, 527–536 (1997)

    CAS  Article  Google Scholar 

  18. 18

    Bach, S. et al. Roscovitine targets, protein kinases and pyridoxal kinase. J. Biol. Chem. 280, 31208–31219 (2005)

    CAS  Article  Google Scholar 

  19. 19

    Shah, K., Liu, Y., Deirmengian, C. & Shokat, K. M. Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates. Proc. Natl Acad. Sci. USA 94, 3565–3570 (1997)

    ADS  CAS  Article  Google Scholar 

  20. 20

    Sun, K.-H., De Pablo, Y., Vincent, F. & Shah, K. Deregulated Cdk5 promotes oxidative stress and mitochondrial dysfunction. J. Neurochem. 107, 265–278 (2008)

    CAS  Article  Google Scholar 

  21. 21

    Tarricone, C. et al. Structure and regulation of the CDK5-p25(nck5a) complex. Mol. Cell 8, 657–669 (2001)

    CAS  Article  Google Scholar 

  22. 22

    Hu, E., Kim, J. B., Sarraf, P. & Spiegelman, B. M. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ. Science 274, 2100–2103 (1996)

    ADS  CAS  Article  Google Scholar 

  23. 23

    Shao, D. et al. Interdomain communication regulating ligand binding by PPAR-γ. Nature 396, 377–380 (1998)

    ADS  CAS  Article  Google Scholar 

  24. 24

    Rangwala, S. M. et al. Genetic modulation of PPARγ phosphorylation regulates insulin sensitivity. Dev. Cell 5, 657–663 (2003)

    CAS  Article  Google Scholar 

  25. 25

    Sharma, P. et al. Phosphorylation of MEK1 by cdk5/p35 down-regulates the mitogen-activated protein kinase pathway. J. Biol. Chem. 277, 528–534 (2002)

    CAS  Article  Google Scholar 

  26. 26

    Hornbeck, P. V. et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res. 40, D261–D270 (2012)

    CAS  Article  Google Scholar 

  27. 27

    Puigserver, P. et al. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92, 829–839 (1998)

    CAS  Article  Google Scholar 

  28. 28

    Ohno, H., Shinoda, K., Spiegelman, B. M. & Kajimura, S. PPARγ agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein. Cell Metab. 15, 395–404 (2012)

    CAS  Article  Google Scholar 

  29. 29

    Flaherty, K. T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694–1703 (2012)

    CAS  Article  Google Scholar 

  30. 30

    Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358–362 (2006)

    ADS  CAS  Article  Google Scholar 

  31. 31

    Banks, A. S. et al. Dissociation of the glucose and lipid regulatory functions of FoxO1 by targeted knockin of acetylation-defective alleles in mice. Cell Metab. 14, 587–597 (2011)

    CAS  Article  Google Scholar 

  32. 32

    Barrett, S. D. et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg. Med. Chem. Lett. 18, 6501–6504 (2008)

    CAS  Article  Google Scholar 

  33. 33

    Albeck, J. G., Mills, G. B. & Brugge, J. S. Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals. Mol. Cell 49, 249–261 (2013)

    CAS  Article  Google Scholar 

  34. 34

    Lau, K. S. et al. In vivo systems analysis identifies spatial and temporal aspects of the modulation of TNF-α-induced apoptosis and proliferation by MAPKs. Sci. Signal. 4, ra16 (2011)

    PubMed  PubMed Central  Google Scholar 

  35. 35

    Robinson, M. J., Stippec, S. A., Goldsmith, E., White, M. A. & Cobb, M. H. A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation. Curr. Biol. 8, 1141–1150 (1998)

    CAS  Article  Google Scholar 

  36. 36

    Patricelli, M. P. et al. In situ kinase profiling reveals functionally relevant properties of native kinases. Chem. Biol. 18, 699–710 (2011)

    CAS  Article  Google Scholar 

  37. 37

    McAllister, F. E. et al. Mass spectrometry based method to increase throughput for kinome analyses using ATP probes. Anal. Chem. 85, 4666–4674 (2013)

    CAS  Article  Google Scholar 

  38. 38

    Rappsilber, J., Mann, M. & Ishihama, Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nature Protocols 2, 1896–1906 (2007)

    CAS  Article  Google Scholar 

  39. 39

    Kettenbach, A. N. & Gerber, S. A. Rapid and reproducible single-stage phosphopeptide enrichment of complex peptide mixtures: application to general and phosphotyrosine-specific phosphoproteomics experiments. Anal. Chem. 83, 7635–7644 (2011)

    CAS  Article  Google Scholar 

  40. 40

    Ting, L., Rad, R., Gygi, S. P. & Haas, W. MS3 eliminates ratio distortion in isobaric multiplexed quantitative proteomics. Nature Methods 8, 937–940 (2011)

    CAS  Article  Google Scholar 

  41. 41

    McAlister, G. C. et al. Increasing the multiplexing capacity of TMTs using reporter ion isotopologues with isobaric masses. Anal. Chem. 84, 7469–7478 (2012)

    CAS  Article  Google Scholar 

  42. 42

    Huttlin, E. L. et al. A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174–1189 (2010)

    CAS  Article  Google Scholar 

  43. 43

    Eng, J. K., McCormack, A. L. & Yates, J. R. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J. Am. Soc. Mass Spectrom. 5, 976–989 (1994)

    CAS  Article  Google Scholar 

  44. 44

    Elias, J. E. & Gygi, S. P. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nature Methods 4, 207–214 (2007)

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We thank E. Rosen for providing us with the adiponectin Cre mice before their initial publication; members of the Spiegelman laboratory (Dana-Farber Cancer Institute) and D. Cohen (Brigham and Women's Hospital) for discussions; and C. Palmer and K. LeClair for reading the manuscript. B.M.S. acknowledges National Institutes of Health (NIH) grant DK31405. A.B. acknowledges NIH grant DK93638, the Harvard University Milton Fund, and the Harvard Digestive Disease Center, Core D.

Author information

Affiliations

Authors

Contributions

A.B., B.M.S., F.E., S.G., J.P.C., M.J. and G.S. designed the experiments. A.B., D.B., F.E., J.C.P. and P.Z. performed the experiments. A.B., B.M.S. and F.E. wrote the manuscript.

Corresponding authors

Correspondence to Alexander S. Banks or Bruce M. Spiegelman.

Ethics declarations

Competing interests

B.M.S. is a consultant to and shareholder in Ember Therapeutics. The remaining authors declare no competing interests.

Extended data figures and tables

Extended Data Figure 1 Metabolic profiling of adipose-specific Cdk5-KO mice on a standard chow diet.

ae, Fasting plasma levels of glucose (a), insulin (b), total triacylglycerols (c), free fatty acids (FFA) (d) and total cholesterol (e) (n = 16 (control) and 17 (KO)). f, g, Body weights (f) and intraperitoneal glucose tolerance test (g). Mice were 12 weeks of age (n = 14 (control) and 11 (KO)). No significant differences were observed. Error bars indicate s.e.m.

Extended Data Figure 2 Energy homeostasis of adipose-specific Cdk5-KO mice maintained on a high-fat diet.

af, After a 48-h acclimatization period, singly housed mice were monitored for oxygen consumption (VO2) (a), carbon dioxide production (VCO2) (b), respiratory exchange ratio (RER) (c), ambulatory locomotor activity (d), cumulative food intake (e) and body weights (f) (n = 8 per group). Shaded areas signify the dark phase of the light cycle. No significant differences were observed. Error bars indicate s.e.m.

Extended Data Figure 3 Activity of alternative kinases in adipose tissue from Cdk5-KO mice.

Brown adipose tissue protein lysates from mice maintained on a high-fat diet for 12 weeks. Blotting for phospho-p38, phospho-JNK and phospho-S473 and pT308 AKT was performed before loading for total protein amounts.

Extended Data Figure 4 Conservation of the sites on MEK2 phosphorylated by Cdk5.

Mouse MEK2 T395/T397 corresponds to human MEK2 T394/T396. These sites share identity with MEK1 T386/T388 in both humans and mouse. Cdk5 has previously been shown to phosphorylate MEK1 at T286, a site not shared with MEK2. ERK has been shown to phosphorylate MEK1 T386 and contribute to regulation of kinase activity31. Homo, Homo sapiens; trog, Pan troglodytes; mus, Mus musculus; rat, Rattus norvegicus; bos, Bos taurus; canis, Canis lupus familiaris.

Extended Data Figure 5 Body weight of control and of adipose-specific Cdk5-KO mice maintained on a high-fat diet after treatment with PD0325901.

Treatment similar to that in Fig. 4a–c. The body weights are not significantly different by ANOVA. Error bars indicate s.e.m.

Extended Data Figure 6 Effects of PD0325901 treatment on ob/ob mice.

ac, Glucose tolerance test (a), adiponectin levels (b) and body weights (c) of ob/ob mice treated with PD0325901 (n = 7 (vehicle) and 8 (PD)). *P ≤ 0.05 by Student’s t-test. Error bars indicate s.e.m.

Extended Data Figure 7 Inflammatory markers in epididymal white adipose tissue from ob/ob mice treated with MEK inhibitors.

Gene expression analysis was performed on M1 macrophage markers Nos2 and tumour necrosis factor-α (TNF-α); M2 macrophage markers Arg1, Chil3, Il10, Itgax, Clec10a/Mgl1 and Mgl2; chemotactic ligand Ccl2 and receptor Ccr2; and macrophage surface markers Emr1, Cd68 and Csf1r (n = 7 or 8 mice per group as in Fig. 5f, h). Gene expression was analysed by ANOVA. Error bars indicate s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001.

Extended Data Figure 8 Schematic model of PPARγ regulation at S273.

a, In the lean state, PPARγ is not phosphorylated. b, In the obese state, S273 phosphorylation is driven by both Cdk5 and ERK with CDK5 repressing MEK and ERK activity. c, Cdk5-KO results in derepression of MEK and ERK kinases and increased phosphorylation of S273 PPARγ. d, MEK inhibition markedly decreases S273 PPARγ phosphorylation. e, PPARγ ligands, including the thiazolidinediones, block the accessibility of S273 PPARγ by either ERK or CDK5 kinases.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Banks, A., McAllister, F., Camporez, J. et al. An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ. Nature 517, 391–395 (2015). https://doi.org/10.1038/nature13887

Download citation

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing